Dr. Stewart on the Impact of Delaying Approval on Overall Survival
David J. Stewart, MD, head, Division of Medical Oncology, University of Ottawa/The Ottawa Hospital, discusses a study that investigated the impact of delaying approval on overall survival.
David J. Stewart, MD, head, Division of Medical Oncology, University of Ottawa/The Ottawa Hospital, discusses a study that investigated the impact of delaying approval on overall survival, presented at the 2015 World Conference on Lung Cancer.
He and his colleagues looked at randomized trials in different kinds of cancer, published between 2000 and 2015. They took the average improvement in life expectancy in those clinical trials and multiplied it by the number of people dying from that malignancy in North America and worldwide. Their objective was to calculate the number of life years that would be lost per year of delay in getting the drug approved.
In order to illustrate this, Stewart and his team looked at 21 drugs and 11 malignancies. After adding up the results, they discovered that over 2.5 million life years were lost per year of delay in getting the drug approved. This is one for every 12 seconds of delay worldwide and more than 20,000 life years lost in North America alone.
Adaptive NSCLC Trial Misses Target Efficacy, Reaches Clinical Benefit in Some Patients
September 16th 2024The PIONeeR trial, evaluating combinations of immunotherapy drugs for advanced NSCLC, identified durvalumab plus ceralasertib as a promising treatment option, demonstrating long-term clinical benefit in some patients.
Read More
Adagrasib Outperforms Docetaxel for Pretreated KRAS G12C-Mutant Non-Small Cell Lung Cancer
September 15th 2024Adagrasib demonstrated superior outcomes to docetaxel in patients with previously treated KRAS G12C-mutated non-small cell lung cancer, even among those with baseline brain metastases.
Read More
Zipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC
September 14th 2024Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.
Read More
